Background: Recent outbreaks of highly pathogenic H5N1 viruses in humans indicate that no endogenous protection exists in the general population. Vaccination programmes against this new pathogen require synthesis of endogenous antibodies and cannot provide any immediate protection in the event of a pandemic. Passive immunization with humanized neutralizing monoclonal antibodies can prove to be promising in preventing a catastrophic pandemic. Methods: A murine monoclonal antibody (mAb) 3B1 of immunoglobulin M isotype was switched to a chimeric immunoglobulin G1. BALB/c mice were used to study the protective efficacy of the chimeric mAbs against a lethal H5N1 virus challenge with strains from clades 1 and 2.1.
The continued circulation of H5N1 strains of influenza A virus in poultry, and recent sporadic outbreaks in humans, serve as a warning of a future influenza pandemic. Present vaccine strategies require endogenous synthesis of antibodies and will not provide immediate protection against H5N1 infections in the event of a pandemic. Currently available antiviral treatment options are limited [1, 2] . Furthermore, isolation of drug-resistant viral strains in the recent past warrants an urgent need for alternative strategies for treatment and prophylaxis [3] [4] [5] . Antibody-based therapy using polyclonal and monoclonal antibodies (mAbs) is currently used in the prophylaxis of several infections, such as hepatitis A virus, hepatitis B virus and respiratory synctial virus infections [6] . Passive immunization by transfusion of human convalescent sera was associated with a 50% reduction in mortality during an influenza pandemic and has been shown to be effective against H5N1 influenza A viral infection [7] [8] [9] . Equine F(ab′) 2 fragments specific for H5N1 have also been used for efficacious prophylaxis and therapy in a mouse model [10] .
Although murine mAbs are used for clinical applications, they have major limitations. Formation of immune complexes might reduce the effectiveness of treatment by rapid removal of only partially saturated mAbs from the system. In addition, treated patients develop human antimurine antibodies (HAMA) [11] that might reduce the effectiveness of any subsequent treatments for influenza or other diseases because of Introduction rapid clearance of the murine mAbs from the system by the HAMA. Human mAbs would have been the ideal answer; however, obtaining blood from healthy volunteers immunized with H5N1 and immortalization of B-cells remains a difficult task [12] . One alternative is to construct mouse-human chimeric antibodies, which have human constant regions to provide effector functions and mouse variable regions that bind antigens [13] ; such humanized molecules would be largely human in composition and significantly less immunogenic. Also, the isotype of the murine mAb could be switched to a more effective isotype for more valuable effector functions [14] .
One of the necessary steps to prepare for a potential pandemic is to put in place a prophylactic regimen that will protect those who are in contact with infected individuals. Hanson et al. [15] reported that passive immunoprophylaxis and therapy with a humanized mAb is efficacious against lethal challenge with an H5N1 strain. In the present report, a highly neutralizing murine immunoglobulin M (IgM) mAb was switched to a chimeric immunoglobulin G1 (IgG1) while retaining its specificity for the antigen. We evaluated the prophylactic and therapeutic efficacy of this chimeric mAb against two highly pathogenic H5N1 virus strains from clades 1 and 2.1 in a murine model. Efficacy was determined by observation of weight loss, survival and kinetics of viral load clearance in the lungs of the infected mice. [16] . Briefly, the synthesized haemagglutinin and neuraminidase genes were cloned into a dual-promoter plasmid for influenza A reverse genetics. Dual-promoter plasmids were obtained from the US Center for Disease Control and Prevention (Atlanta, GA, USA). The reassortant virus was rescued by transfecting plasmids containing the haemagglutinin and neuraminidase genes together with the remaining six gene plasmids derived from A/Puerto Rico/8/34 (H1N1) into coculture of 293T and Madin-Darby canine kidney (MDCK) cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Stock viruses were propagated in the allantoic cavities of 11-day-old embryonated chicken eggs at 35°C for 36 h. All experiments with highly pathogenic viruses were conducted in a biosafety level three or higher containment facility in compliance with the US Centers for Disease Control and Prevention/the US National Institutes of Health and the World Health Organization recommendations [17, 18] and were also approved by the Agri-Food and Veterinary Agency (Singapore) and the MOH. mAb production BALB/c mice were immunized twice subcutaneously at regular intervals of 2 weeks with inactivated whole virus from A/Indonesia/TLL014/2006 in 0.1 ml of phosphate-buffered saline (PBS), which was emulsified with an equal volume of adjuvant (SEPPIC, Paris, France). Thereafter, mice were boosted intravenously with 25 mg of the whole virus antigen 3 days before the fusion of splenocytes with SP2/0 cells. Hybridoma culture supernatants were screened by immunofluorescence assays. Hybridomas that produced specific antibodies were cloned by limiting dilution, expanded and further subcultured. The hybridoma cultures were harvested and cell debris was removed by centrifugation at 400×g for 10 min. The supernatant was collected and stored at -20°C. Positive clones were checked for isotype by using a One-Minute Isotyping Kit (Amersham Bioscience, Buckinghamshire, UK) as described in the manufacturer's protocol. The mAbs were purified using protein A sepharose beads (Millipore, Billerica, MA, USA). Purity of the antibodies was confirmed by SDS-PAGE analysis. The mAbs were then tested for neutralization activity by standard haemagglutination inhibition (HI) assays as described below.
Methods

Viruses
Cloning of chimeric IgG1 expression plasmid
Design of the expression vector was as described by Jostock et al. [19] . Briefly, human antibody constant regions encoding the kappa light chain and the IgG1 heavy chain were amplified and cloned into a modified pCMV/myc/ER plasmid with an internal ribosome entry site of encephalomyocarditis virus inserted in between them. Unique restriction sites were introduced to allow for insertion of the variable regions of the heavy and light chains in frame with the constant regions.
Messenger RNA was prepared from the mAb 3B1 hybridoma cells and used in first-strand complementary DNA (cDNA) synthesis with random hexamers. The total cDNA was used as template to amplify both the variable heavy and light chain using the primers and protocols of the mouse single-chain variable fragment recombinant antibody phage system (Amersham Biosciences). The resultant products were cloned into pCR-Script (Stratagene, La Jolla, CA, USA) for sequencing. Sequence-specific primers were then designed and used for amplification of the variable regions, which were then cloned into the expression vector. Expression of this construct led to the production of chimeric antibodies containing 33% of the sequences as mouse variable regions from mAb 3B1 and 67% of the sequences as human constant regions for IgG1.
Transient expression of chimeric antibodies and purification
Chimeric antibodies were expressed using the Freestyle 293 Expression system (Invitrogen) to obtain antibodies produced in a defined serum-free medium. The abovementioned construct was transfected into 293-F cells using 293fectin (Invitrogen) and supernatants were collected 120 h after transfection. The chimeric antibody 3B1 (ch3B1) was purified using protein A sepharose beads (Millipore). The purity of ch3B1 was confirmed by SDS-PAGE and immunoblot analysis, using horseradish peroxidase (HRP)-labelled antihuman immunoglobulin (DAKO, Glostrup, Denmark), was used to confirm introduction of the human constant regions.
Antigen-binding affinity of ch3B1
To determine the antigen binding affinity of the ch3B1 against H5N1 antigen, indirect ELISA was performed. Purified inactivated whole H5N1 viral antigen (A/Indonesia/CDC669/2006) of 32 haemagglutination (HA) units in 100 ml of coating buffer (0.1 mol/l carbonate/ bicarbonate, pH 9.6) was coated on ELISA plates and incubated overnight at 4°C. After subsequent blocking with 3% milk, the plates were incubated for different time intervals (10, 15, 20, 30, 45 and 60 min) with 1 mg/ ml of murine mAb 3B1 or ch3B1 diluted in PBS with 0.05% Tween 20. An aliquot (100 ml) of rabbit antimouse IgG or rabbit antihuman IgG conjugated with HRP diluted (1:1000) in PBS was added to the respective wells. The reaction was incubated at 37°C for 1 h and was subsequently developed with 100 ml of 3,3′,5,5′-tetramethyl benzidine (Sigma, St Louis, MO, USA). The reaction was stopped with 25 ml of 1 mol/l sulphuric acid and the absorbance was measured at 450 nm using an ELISA plate reader (Tecan, Grodig, Austria).
Haemagglutination inhibition assays
HI assays were performed as described previously [20] . Briefly, the 3B1 mAb was serially diluted (twofold) in V-bottom 96-well plates and mixed with 4 HA units of influenza A virus. Plates were incubated for 30 min at room temperature and 1% chicken red blood cells were added to each well. The HI end point was the highest mAb dilution in which agglutination was not observed.
Microneutralization assays
Neutralizing activity of ch3B1 against H5N1 strains was analyzed by microneutralization assays as previously described [20, 21] . Briefly, mAb was serially diluted twofold and incubated with 100 50% tissue culture infective doses (TCID 50 ) of different clades of H5N1 strains for 1 h at room temperature and plated in duplicate onto MDCK cells grown in a 96-well plate. The TCID 50 of each of the H5N1 strains in the MDCK cell culture was determined by the Reed and Muench method [22] . The neutralizing titre was expressed as the reciprocal of the highest mAb dilution that completely prevented cytopathic effects in MDCK cells.
Immunization and challenge
Inbred SPF BALB/c mice aged 4-6 weeks were used for the challenge studies. Mice (n=10 per group) were intranasally infected with 5 50% mouse lethal dose (MLD 50 ) of two different H5N1 strains (RG-A/ Hongkong/213/2003 from clade 1 and A/Indonesia/ TLL013/06 from clade 2.1). All animal experiments were carried out in accordance with the guides for animal experiments performed at the National Advisory Committee for Laboratory Animal Research (Singapore) and experimental protocols were reviewed and approved by the Institutional Animal Care and Use Committee of the Temasek Lifesciences Laboratory (National University of Singapore, Singapore).
Prophylactic efficacy
To determine the prophylactic efficacy, mice were pretreated intraperitoneally with 2.5, 5, 10 or 0 mg/kg (PBS) of ch3B1 prior to the viral challenge. After 24 h, mice were challenged with 5 MLD 50 of the two different H5N1 strains. Mice were observed daily to monitor body weight and mortality until all animals died or until day 14 post-viral challenge.
Therapeutic efficacy
To determine the therapeutic efficacy of the mAb, each group of mice was challenged with 5 MLD 50 of the two different H5N1 strains. At 24 h after viral challenge, the mice were treated via intraperitoneal route with 2.5, 5, 10 or 0 mg/kg (PBS) of ch3B1.
Duplicate sets of mice were maintained for each experimental group with animals infected with clade 2.1 for quantitative PCR (qPCR) and histopathology experiments. On days 3, 6 and 9 post-viral challenge, mice were euthanized by a lethal dose of sodium pentobarbital. For determination of viral loads using qPCR, lungs were harvested and homogenized in 2 ml of Trizol (Invitrogen) using a tissue homogenizer and total RNA was extracted. For histopathology, a lung sample was collected in 10% (w/v) buffered formalin solution, embedded in paraffin and sectioned. Sections were stained with hematoxylin and eosin and were analyzed for pathology.
Determination of viral load by real-time PCR
Total RNA (500 ng/sample) was used for cDNA synthesis. The cDNA suspension was used for amplification in a real-time qPCR reaction. A DyNAmo™ Capillary SYBR Green qPCR Kit (Finnzymes, Espoo, Finland) was used in the PCR assay. Briefly, the cDNA was amplified in 20 ml containing 0.25 mmol of forward primer (5′-TGCCCAAGACATACTGGAAA-3′), 0.25 mmol of reverse primer (5′-AGGAGCCATCCAGCTACACT-3′) and 1× of the DyNAmo master mix. Reactions were performed in a Light Cycler (Roche, Mannheim, Germany) with the following conditions: 10 min at 95°C, followed by 50 cycles of 95°C for 10 s, 57°C for 5 s and 72°C for 9 s. Fluorescence signals from these reactions were captured at the end of the extension step in each cycle. To determine the specificity of the assay, PCR products were subjected to melting curve analysis at the end of the assay (65-95°C, 0.1°C/s). Plasmids containing the target sequence were used as positive controls. To determine the dynamic range of real-time qPCR, serial dilutions of in vitro transcribed RNA containing the target sequence were made and subjected to the assay. The assay was able to distinguish 10-fold differences in concentration over a range of 1,000-10 9 copies. Relative quantification in triplicate for each experimental sample was obtained by using the standard curve method.
Isolation and analysis of in vitro escape mutants
Escape mutants were selected as described previously [23] . Briefly, virus incubated with an excess of mAb for 1 h were inoculated into 11-day-old embryonated chicken eggs. The eggs were incubated at 37°C for 48 h. Virus was harvested and used for cloning under limiting dilution in embryonated chicken eggs. RNA was extracted from the allantoic fluid. The haemagglutinin gene was reverse transcriptase (RT)-PCR amplified and cloned into a TA-cloning vector (Promega) and several clones were sequenced. The sequences of individual clones were analyzed by comparison with the sequence of the parent virus.
Isolation and analysis of in vivo escape mutants from lung samples
Escape mutants were analyzed on day 3 from the groups of mice challenged with clade 2.1 virus and treated with 5 mg/kg of ch3B1. The lung samples of the infected mice were removed aseptically and homogenized using a pestle and mortar. The lung homogenate was then inoculated into embryonated chicken eggs under limiting dilutions. The virus was harvested after 48 h and the RNA was isolated from the allantoic fluid. The haemagglutinin gene was RT-PCR amplified and cloned into a TA-cloning vector (Promega) and several clones were sequenced.
Results
ch3B1 retains characteristics of murine mAb 3B1
A panel of mAbs against influenza haemagglutinin was screened for efficient neutralization of different strains of H5N1 viruses. Epitope mapping of the mAb was done using escape mutant analysis. Upon sequencing 25 clones, 19 clones showed a mutation at Ser155, indicating that this amino acid was involved in the epitope of mAb 3B1. The mAb 3B1 (IgM) was chosen for humanization and therapeutic studies in a mouse model on the basis of its reactivity with the H5N1 viruses and high HI titres (Table 1) . In order to chimerize the mAb, a plasmid construct was made, which expressed antibodies with human IgG1 constant domains and murine variable domains from mAb 3B1 upon transfection. A positive western blot with HRP-conjugated antihuman IgG and negative blot with antimouse IgG confirmed the presence of human constant regions.
Despite the change in isotype, ch3B1 maintained the characteristics of the murine IgM mAb, although there appeared to be a decrease in affinity (Figure 1 however, the ch3B1 reached an OD 450 of approximately 1.0 at 20-30 min. ch3B1 maintained its specificity for the antigen as it continued to recognize clade 1 and 2.1 virus strains in an indirect immunofluorescence assay, as did the murine mAb 3B1 (data not shown). The ch3B1 also neutralized the H5N1 viruses with high efficiency as is evident from the HI titres and in vitro neutralization assays (Table 1) .
Prophylactic treatment with ch3B1 protects mice from lethal viral challenge
We examined the protective efficacy of ch3B1 in mice challenged with clades 1 or 2.1 strains of H5N1 virus ( Figure 2 ). All mice pretreated with a single dose of 5 or 10 mg/kg of ch3B1 were protected from death following lethal challenge with 5 MLD 50 of both clades of H5N1 viruses (100% protection; Figure 2A and 2C), whereas all untreated control mice lost >23% of their original body weight on day 4 and died from viral infection by day 6 post-viral challenge. Mice pretreated with 5 and 10 mg/kg of ch3B1 lost <13% and 10% of their original body weight by day 5, respectively, and regained their body weight by day 14 post-viral challenge ( Figure 2B and 2D) . Moreover, mice pretreated with the lowest concentration of 2.5 kg/mg of ch3B1 lost <15% of their original body weight. At this concentration, ch3B1 showed protection of 80% and 90% against clade 2.1 ( Figure 2C ) and clade 1 (Figure 2A) virus challenge, respectively. To verify whether ch3B1 neutralized the virus in vivo, lung viral copies were determined by qPCR at various time points during the infection (Figure 3) . Lungs of infected mice were harvested on days 3, 6 and 9 post-viral challenge. The viral numbers peaked on day 3 post-viral challenge and the control untreated mice were dead by day 6 ( Figure 3A) . The antibody treatment significantly reduced the viral numbers in all the treated mice. Mice treated with 10 mg/kg of ch3B1 showed approximately 100-fold less virus than the control on day 3 and undetectable viral copies (<1,000 copies) on day 6. Mice treated with 5 mg/kg of ch3B1 showed 10-fold reduction in the viral load on day 3 compared with the untreated control and no detectable virus was observed by day 9. The mice treated with 2.5 mg/kg did not show significant reduction in viral loads when compared with untreated control on day 3. However, reduction in viral loads was observed on day 6 from that of day 3 and viral loads were undetectable on day 9. This could not be compared with the untreated control as the mice in this group did not survive beyond day 6. Sera of the survivor mice were tested by HI assays to detect any humoral immune response to the challenge virus. The titre of the murine antiviral antibody was 2 log 2 HI on day 10 and reached 4 log 2 HI by day 14 (Figure 4 ). The mice receiving 2.5 mg/kg of the ch3B1 showed maximum immune response to the challenge virus.
Therapeutic treatment with ch3B1 protects mice from lethal viral challenge
To determine the therapeutic efficacy of ch3B1 against H5N1 lethal challenge, mice were challenged with 5 MLD 50 of clades 1 or 2.1 virus strains ( Figure 5 ). At 24 h post-viral challenge, the mice were treated with 2.5, 5 or 10 mg/kg of ch3B1. ch3B1 was able to protect 100% of mice from both clades of viruses at concentrations of 5 and 10 mg/kg ( Figure 5A and 5C ). Even at 2.5 mg/kg, ch3B1 could protect 80% and 70% of mice from lethal challenge with clades 2.1 and 1 virus, respectively. The body weight of the mice was measured as an indication of the progress of infection ( Figure 5B and 5D). The untreated group of mice infected with virus showed a decrease in body weight before succumbing to the infection by day 4. Mice treated with 10 mg/kg showed only approximately 7% loss in body weight on day 5 and steadily regained the body weight by day 14 post-viral challenge. Mice treated with 5 and 2.5 mg/kg 
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lost 12% and 14% of their body weight, respectively, but gradually regained it by day 14. Histopathology studies were carried out only for the lungs of mice treated with different doses of ch3B1 postviral challenge with clade 2.1 virus (Figure 6 ). On day 6 post-infection, lungs of untreated mice had pulmonary lesions consisting of moderate to severe necrotizing bronchitis and moderate to severe histiocytic alveolitis with associated pulmonary oedema ( Figure 6B ).The uninfected mice did not have lesions in the lungs (Figure 6A ). Mice treated 24 h post-viral challenge with 2.5 mg/kg of ch3B1 had minimal to moderate bronchitis ( Figure 6C ) and mice treated with 5 and 10 mg/kg of ch3B1 had minimal bronchitis ( Figure 6D and 6E) .
Lung viral copies were determined at various time points during the infection by qPCR. Lungs of infected mice were harvested on days 3, 6 and 9 post-viral challenge. The viral numbers peaked on day 3 post-viral challenge and the control untreated mice were dead by day 6 ( Figure 3B ). The 10 mg/kg ch3B1 treated mice showed a log 10 10 2.5 -fold reduction in viral numbers than untreated mice on day 3 and their viral load was below the detection limit (1,000 copies) on day 6. Mice treated with 5 mg/kg showed >6-fold reduction in viral loads on day 3 compared with the untreated control and no detectable virus was observed by day 9. Similar reduction in viral loads at a lower level was observed in mice treated with 2.5 mg/kg when compared with the untreated control on day 3 and was undetectable on day 9. These data indicate that ch3B1 conferred significant protection to the mice when administered 24 h postviral challenge.
HI assays were performed using the sera of the survivor mice to detect any humoral immune response to the challenge virus. The titre of the murine antiviral antibody was approximately 2 log 2 HI on day 10 and reached 4 log 2 HI by day 14 (Figure 7) . The mice who received 2.5 mg/kg of the ch3B1 showed maximum immune response to the challenge virus.
Escape mutants to the mAb 3B1 were detected by day 3 post-viral challenge A B haemagglutinin gene. Of the 35 clones, 22 had one mutation at S155I and 7 of the clones had two mutations at S155I and R189W. ch3B1 was unable to inhibit HA induced by the escape mutants, indicating that it does not neutralize the escape mutants.
Discussion
A major concern regarding the use of mAbs in human clinical applications is their potential to elicit HAMA responses and poor recognition of effector domains by the human system [24] . To overcome such problems, murine antibodies have been genetically manipulated to progressively replace their murine content with their human counterparts in an effort to 'humanize' the antibodies [25] . Previously, only a single study has been reported in which a chimeric antibody has shown efficacious protection against lethal H5N1 infection [15] . Recently, broadly cross-reactive mAbs against H1N1 and H5N1 viruses have been recovered from combinatorial display libraries constructed from human IgM-positive memory B-cells [26] . Sui et al. [27] have also used in vitro methodologies to isolate broad-spectrum human neutralizing antibodies against haemagglutinin that show potent in vivo efficacy against H5N1 and H1N1 viruses.
The present study demonstrates chimerization of a murine antibody 3B1 involving isotype switching from IgM to IgG and the subsequent use of the chimeric antibody in a prophylactic and therapeutic study against lethal H5N1 infections. Previous studies have shown that isotype switching results in a reduction and often a loss in affinity for the antigen molecule [14] . In the case of ch3B1, the switch in isotype resulted in a slightly lower binding affinity than its parent murine antibody, presumably because of the overall process of chimerization. A loss of avidity contribution on switching from IgM to IgG also cannot be ruled out.
Passive administration of antibodies remains a strategy that can be explored against pandemic influenza. The prophylactic or therapeutic administration of ch3B1 in a single dose showed 100% protection against lethal H5N1 influenza in a mice model. We demonstrated the protective potential of the mAb against two clades of virus that have been responsible for recent outbreaks. We observed 100% protection against clades 1 and 2.1 of H5N1 viruses using 10 and 5 mg/kg of ch3B1. A dose of 5 mg/kg provided sufficient protection and resulted in virus elimination at 9 days post-viral challenge. A dose of 10 mg/kg eliminated the virus after only 6 days post-viral challenge. Therapy with ch3B1 helped to control the initial course of infection, thus allowing the animal to mount an effective immune response. Our studies suggest that the use of passive antibody therapy can be effective as a containment option in the event of pandemic influenza.
The escape mutant analyses of the mAb 3B1, both in vitro and in vivo, indicate that ser155 is the major determinant of the epitope of mAb 3B1. The presence of the amino acid of the epitope in a highly antigenic loop (located at positions 150-160) explains its high neutralizing capacity [28] ; however, this loop is also known to be highly susceptible to mutations [28, 29] and therefore explains the ease with which escape mutants seem to emerge against this epitope. By contrast, the identification of mutants of a second amino acid at position 189 suggests that the virus reacts with the mAb at two sites. The fact that the antibody reacts with two antigenic sites rather than one might offer the virus broader possibilities of escape if a mutation in either site could confer resistance to neutralization. However, the fact that we could not isolate a single mutant at position 189 suggests that this position might be less prone to mutation. The isolation of escape mutants from the infected mice against this chimeric mAb might be a concern for its use as therapy; however, total elimination of the escape mutants by day 14 implies that the animal's immune response could successfully eliminate the virus from the system. Inclusion of other mAbs that can neutralize the escape mutants in combination with ch3B1 might be an effective therapy to be explored in the future. It remains 
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to be tested whether any human antichimeric antibody response will be seen when ch3B1 is administered to humans. It might be necessary to further humanize the mAb by grafting of the complementarity-determining regions and preclinically evaluate the mAb in subhuman primates. The effectiveness of a single dose for both prophylaxis and treatment in the mouse studies implies that the efficacy of the antibody might still be maintained even if the chimeric antibody does illicit an immune response itself. 
